Literature DB >> 25086073

The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis.

Nevsun Inanc1, Sibel Yilmaz-Oner2, Meryem Can2, Tuulikki Sokka2, Haner Direskeneli2.   

Abstract

OBJECTIVE: To investigate the effect of depression, anxiety, fatigue, and fibromyalgia (FM) on the remission status in patients with rheumatoid arthritis (RA), defined according to the 28-joint count Disease Activity Score (DAS28)-erythrocyte sedimentation rate (ESR) and the Boolean-based new American College of Rheumatology/European League Against Rheumatism remission criteria.
METHODS: The subjects were patients with RA who participated in a hospital-based observational cohort. Patients who met the DAS28-ESR remission criteria at their latest visit were invited to participate in our study. The patient groups fulfilling or not fulfilling the Boolean remission criteria were identified and compared with each other with regard to the presence of depression, anxiety, fatigue (0-50), and FM. The relationship between psychosocial factors and Simplified Disease Activity Index (SDAI) remission, which is the index-based definition of remission in RA, was also investigated.
RESULTS: A total of 87 out of 428 patients (20%) with RA met the DAS28-ESR remission criteria and 32 (37%) of these also met the Boolean remission criteria, while 55 (63%) did not. Forty patients were also in SDAI remission. In the Boolean remission group, 2 patients had depression and 2 had anxiety (p = 0.004). In the Boolean nonremission group, 19 patients had depression and 13 had anxiety (p = 0.04). Continuous scales of anxiety (3.34 ± 3.76 vs 5.83 ± 4.70, p = 0.012) and depression (2.18 ± 2.75 vs 4.63 ± 4.10, p = 0.001) were also lower in the Boolean remission group in comparison with the nonremission group. Though FM syndrome was detected in only 1 patient of the Boolean remission group and in 7 patients of the Boolean nonremission group (p = 0.249), patients' polysymptomatic distress scores of FM in the Boolean remission group were significantly lower than those of the nonremission group (3.12 ± 3.25 vs 6.27 ± 5.19, p = 0.001). The mean fatigue scores were 9.5 ± 10.6 in the Boolean remission group and 16.8 ± 12.8 in the Boolean nonremission group (p = 0.006). In multivariate analysis, patient's global assessment (PtGA) and depression were found as the independent discriminators of Boolean-based definition. Similar relationships were also observed between psychosocial factors and SDAI remission.
CONCLUSION: In patients with RA who do not fulfill the Boolean remission criteria, to avoid overtreatment, assessment of anxiety, fatigue, FM, and especially depression must be considered if PtGA scores and disease activity variables are significantly different.

Entities:  

Keywords:  ANXIETY; DEPRESSION; FATIGUE; FIBROMYALGIA; REMISSION; RHEUMATOID ARTHRITIS

Mesh:

Substances:

Year:  2014        PMID: 25086073     DOI: 10.3899/jrheum.131171

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  24 in total

1.  Direct and Indirect Determinants of the Patient Global Assessment in Rheumatoid Arthritis: Differences by Level of Disease Activity.

Authors:  Michael M Ward; Lori C Guthrie; Abhijit Dasgupta
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-03       Impact factor: 4.794

2.  A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers.

Authors:  Alan M Rathbun; Leslie R Harrold; George W Reed
Journal:  Clin Ther       Date:  2016-06-29       Impact factor: 3.393

Review 3.  Patient reported outcomes in rheumatoid arthritis clinical trials.

Authors:  Ana-Maria Orbai; Clifton O Bingham
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

4.  Rheumatoid arthritis: Remission - keeping the patient experience front and centre.

Authors:  Lilian H D van Tuyl; Maarten Boers
Journal:  Nat Rev Rheumatol       Date:  2017-08-31       Impact factor: 20.543

5.  The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis.

Authors:  Fausto Salaffi; Maria Chiara Gerardi; Fabiola Atzeni; Alberto Batticciotto; Rossella Talotta; Antonella Draghessi; Marco Di Carlo; Piercarlo Sarzi-Puttini
Journal:  Rheumatol Int       Date:  2017-09-05       Impact factor: 2.631

6.  The Use of Polysymptomatic Distress Categories in the Evaluation of Fibromyalgia (FM) and FM Severity.

Authors:  Frederick Wolfe; Brian T Walitt; Johannes J Rasker; Robert S Katz; Winfried Häuser
Journal:  J Rheumatol       Date:  2015-06-15       Impact factor: 4.666

7.  Predictors and the optimal duration of sustained remission in rheumatoid arthritis.

Authors:  Sibel Yilmaz-Oner; Ummugulsum Gazel; Meryem Can; Pamir Atagunduz; Haner Direskeneli; Nevsun Inanc
Journal:  Clin Rheumatol       Date:  2019-07-03       Impact factor: 2.980

Review 8.  Fatigue in Rheumatoid Arthritis.

Authors:  Patricia Katz
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

9.  What Does the Patient Global Health Assessment in Rheumatoid Arthritis Really Tell Us? Contribution of Specific Dimensions of Health-Related Quality of Life.

Authors:  Ethan T Craig; Jamie Perin; Scott Zeger; Jeffrey R Curtis; Vivian P Bykerk; Clifton O Bingham; Susan J Bartlett
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11       Impact factor: 4.794

10.  Anxiety impacts rheumatoid arthritis symptoms and health-related quality of life even at low levels.

Authors:  Dana D DiRenzo; Ethan T Craig; Clifton O Bingham Iii; Susan J Bartlett
Journal:  Clin Exp Rheumatol       Date:  2020-03-05       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.